U.S. market Closed. Opens in 3 hours 14 minutes

LYEL | Lyell Immunopharma, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue130.00K84.68M10.65M7.76M657.00K
Cost of Revenue20.25M16.47M14.54M7.47MN/A
Gross Profit-20.12M68.22M-3.88M281.00K657.00K
Operating Expenses247.14M276.50M225.43M219.69M102.75M
Selling, General & Admin66.98M117.31M89.06M46.88M39.15M
Research & Development182.94M159.19M138.69M182.24M63.59M
Other Operating Expenses1.85M1.89M-2.32M-9.43M-35.41M
Operating Income-247.01M-183.12M-214.78M-211.94M-102.09M
Other Expenses / Income-11.08M-178.36M-35.44M7.46M-27.29M
Before Tax Income-234.63M-183.12M-250.22M-204.47M-129.38M
Income Tax Expenses-10.53M-178.36M35.28M-5.94M-8.12M
Net Income-234.63M-4.75M-285.50M-198.53M-121.26M
Interest ExpensesN/AN/AN/AN/AN/A
Basic Shares Outstanding250.98M247.08M242.74M246.58M246.58M
Diluted Shares Outstanding250.98M247.08M242.74M246.58M246.58M
EBITDA-213.84M-165.10M-164.71M-207.64M-100.83M
EBITDA Margin-164,488.46%-194.96%-1,546.53%-2,677.19%-15,347.49%
EBIT-245.16M-183.12M-250.22M-204.47M-129.38M
EBIT Margin-188,586.15%-216.24%-2,349.47%-2,636.31%-19,692.09%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙